PLSE

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.51
Percentage change 2.98	%

Peers: CUTR IRTC NVRO ITGR IART ANIK NEO MDXG STER TMDX

| Held by: VTI IWM VXF IWO SCHA VTWO VFMO IWC ITOT ISMD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.81	Insider Own	71.94%	Shs Outstand	61.52M	Perf Week	-10.63%
Market Cap	1.12B	Forward P/E	-	EPS next Y	-	Insider Trans	0.12%	Shs Float	17.26M	Perf Month	1.50%
Income	-46.13M	PEG	-	EPS next Q	-	Inst Own	9.25%	Short Float	12.28%	Perf Quarter	-13.44%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	16.80%	Short Ratio	12.74	Perf Half Y	46.72%
Book/sh	1.29	P/B	13.72	EPS next Y	-	ROA	-58.03%	Short Interest	2.12M	Perf Year	74.93%
Cash/sh	1.25	P/C	14.15	EPS next 5Y	-	ROE	-70.28%	52W Range	6.59 - 22.69	Perf YTD	44.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	16.76%	ROI	-53.45%	52W High	-22.21%	Beta	1.82
Dividend TTM	-	Quick Ratio	11.93	Sales past 5Y	-30.13%	Gross Margin	-	52W Low	167.63%	ATR (14)	1.43
Dividend Ex-Date	-	Current Ratio	11.93	EPS Y/Y TTM	12.66%	Oper. Margin	-	RSI (14)	47.40	Volatility	8.46% 7.68%
Employees	56	Debt/Eq	0.11	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	3.00	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-7.90%	Payout	-	Rel Volume	1.89	Prev Close	17.14
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Oct 30 AMC	Avg Volume	166.34K	Price	17.65
SMA20	-3.83%	SMA50	0.33%	SMA200	25.86%	Trades		Volume	314,721	Change	2.98%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-21	Initiated	Stephens	Overweight	$28
Mar-11-21	Initiated	Maxim Group	Buy	$40
Jan-26-21	Reiterated	H.C. Wainwright	Buy	$16 → $40
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6 → $16
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral	$26 → $6
Feb-25-19	Initiated	H.C. Wainwright	Buy	$27

Oct-31-24 02:25PM	Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association (Business Wire)
01:58PM	Q3 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
05:01AM	Pulse Biosciences Inc (PLSE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-30-24 04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results (Business Wire)
04:02PM	Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology (Business Wire)
08:00AM	Loading…
Oct-21-24 08:00AM	Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 (Business Wire)
Aug-21-24 07:55AM	Better Cotton Pakistan, PULSE to boost data transparency in cotton farming (Just Style) +13.76%
Aug-13-24 12:38PM	Q2 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +8.05%
Aug-12-24 04:05PM	Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results (Business Wire)
04:01PM	Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors (Business Wire)
Aug-09-24 06:32AM	Pulse Biosciences launches first-in-human pulsed field ablation trial (Medical Device Network)
Aug-08-24 08:00AM	Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System (Business Wire) +9.74%
Aug-01-24 04:05PM	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences (Business Wire)
Jul-29-24 04:05PM	Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024 (Business Wire) -11.36% -5.95%
Jul-09-24 07:27AM	Pulse drops 510(k) plan for PFA device after FDA requests clinical data (MedTech Dive)
06:53AM	Loading…
06:53AM	Pulse Biosciences receives breakthrough device status for CellFX system (Medical Device Network)
Jul-08-24 08:00AM	Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation (Business Wire) +28.71%
Jul-03-24 02:44PM	Pulse Biosciences, Inc. Announces the Closing of its Rights Offering (Business Wire)
Jun-28-24 08:00AM	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering (Business Wire)
Jun-04-24 08:00AM	Pulse Biosciences, Inc. Announces Commencement of Rights Offering (Business Wire)
May-20-24 05:39PM	Pulse Biosciences Moves New Record Date for Rights Offering (MT Newswires) +9.86% +13.40%
04:05PM	Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 (Business Wire)
May-17-24 06:41AM	Pulse Biosciences names new CEO, reassigns former leader (MedTech Dive)
May-16-24 08:00AM	Pulse Biosciences CellFX Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting (Business Wire) +8.68%
May-14-24 05:17PM	Pulse Biosciences Appoints Burke Barrett as President, CEO (MT Newswires) +7.55% -5.59%
04:05PM	Pulse Biosciences Enhances Executive Leadership Team (Business Wire)
May-13-24 09:02AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:00AM	Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System (Business Wire)
May-08-24 06:06AM	Q1 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -9.21%
03:56AM	Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
09:56PM	Loading…
May-07-24 09:56PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024 (InvestorPlace)
05:45PM	Pulse Biosciences Reports Q1 2024 Financial Results Amidst Strategic Business Developments (GuruFocus.com)
04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results (Business Wire)
May-02-24 08:00AM	Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 (Business Wire) +5.92%
Apr-28-24 11:59AM	5 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-24-24 04:05PM	Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 (Business Wire)
Apr-01-24 04:19PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.27%
Mar-29-24 06:30AM	Q4 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 10:53PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023 (InvestorPlace) -8.27%
05:51PM	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 (GuruFocus.com)
04:12PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results (Business Wire)
04:10PM	Pulse Biosciences Announces Plans to Initiate a Rights Offering (Business Wire)
Mar-14-24 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 (Business Wire)
Mar-08-24 01:17PM	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX nsPFA Percutaneous Electrode System (Business Wire)
Feb-14-24 08:00AM	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study (Business Wire) +12.56%
Jan-31-24 08:00AM	Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium (Business Wire)
Jan-02-24 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp (Business Wire) -9.97%
Dec-20-23 08:00AM	Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter (Business Wire) -7.11%
Nov-21-23 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode (Business Wire) +5.59%
Nov-15-23 04:05PM	Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (Business Wire) +9.62%
Nov-14-23 12:52PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.58%
02:15AM	Q3 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-13-23 11:13AM	Pulse Biosciences Inc (PLSE) Reports Decrease in Q3 Losses and Advances in Cardiac Device ... (GuruFocus.com)
08:00AM	Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results (Business Wire)
Nov-10-23 04:56PM	UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call (Business Wire) +11.57%
Oct-30-23 04:05PM	Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023 (Business Wire) +5.76%
Oct-24-23 08:00AM	Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery (Business Wire)
Oct-02-23 08:00AM	Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study (Business Wire)
Sep-29-23 08:00AM	Pulse Biosciences Nanosecond Pulsed Field Ablation (nsPFA) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit (Business Wire) -7.57%
Sep-27-23 08:00AM	Pulse Biosciences First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase (Business Wire)
Aug-24-23 04:05PM	Pulse Biosciences Clarifies Details of Recent S-3 Filing (Business Wire) -8.95%
Aug-17-23 09:31AM	15 Best-Performing Stocks in the Last 12 Months (Insider Monkey)
Aug-11-23 06:28AM	Q2 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +5.56%
Aug-10-23 04:05PM	Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results (Business Wire) -5.66%
Jul-30-23 09:35AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have had a fantastic week as stock increased 31%, and they haven't stopped buying (Simply Wall St.)
Jul-27-23 04:05PM	Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023 (Business Wire) +25.61%
May-22-23 09:30AM	11 Stocks with Heavy Insider Buying in 2023 (Insider Monkey) -7.94%
May-18-23 07:00AM	Pulse Biosciences Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting (Business Wire) -5.73%
May-16-23 12:01PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-12-23 07:43AM	Q1 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
May-11-23 04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results (Business Wire) -8.31%
May-10-23 09:29AM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire)
May-03-23 08:00AM	Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer (Business Wire) +19.19%
May-01-23 08:00AM	Pulse Biosciences Announces $65 Million Private Placement (Business Wire) +5.75%
Apr-27-23 04:05PM	Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023 (Business Wire) +8.97%
Apr-20-23 06:04AM	As Pulse Biosciences, Inc. (NASDAQ:PLSE) hits US$217m market cap, insiders may be dismayed about not purchasing higher quantities (Simply Wall St.)
Apr-05-23 07:46PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 04:05PM	Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results (Business Wire) +35.48%
Mar-10-23 08:30AM	Even after rising 18% this past week, Pulse Biosciences (NASDAQ:PLSE) shareholders are still down 79% over the past five years (Simply Wall St.) +8.78%
Mar-02-23 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023 (Business Wire)
Feb-02-23 08:00AM	Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium (Business Wire)
Dec-10-22 07:24AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) insiders have recently purchased stock and their bets paid off last week as company hit US$108m market cap (Simply Wall St.)
Nov-10-22 04:05PM	Pulse Biosciences Reports Third Quarter 2022 Financial Results (Business Wire) +13.04%
Oct-27-22 04:05PM	Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022 (Business Wire) -5.02%
Oct-14-22 06:17AM	Insider Buying: The Pulse Biosciences, Inc. (NASDAQ:PLSE) Chief Strategy Officer & Director Just Bought 70% More Shares (Simply Wall St.) -5.83%
Oct-06-22 08:00AM	Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions (Business Wire) -9.81%
Oct-01-22 08:50AM	Pulse Biosciences (NASDAQ:PLSE) adds US$29m to market cap in the past 7 days, though investors from a year ago are still down 89% (Simply Wall St.)
Sep-26-22 10:00AM	Pulse Biosciences Lead Therapeutic System Scores FDA Approval For Sebaceous Hyperplasia (Benzinga) +18.30%
08:00AM	Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia (Business Wire)
Sep-21-22 10:03AM	Pulse Biosciences Shifts Core Technology Focus, Reduces Dermatologic Footprint (Benzinga) +7.19%
Sep-20-22 04:26PM	Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation (Business Wire)
Aug-10-22 05:25PM	Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.88%
04:05PM	Pulse Biosciences Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-04-22 08:00AM	Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System (Business Wire)
Jul-27-22 04:05PM	Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022 (Business Wire)
Jun-16-22 04:15PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.37%
Jun-09-22 04:43PM	Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering (Business Wire) -13.18%
Jun-03-22 08:00AM	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering (Business Wire)
May-19-22 08:00AM	Pulse Biosciences, Inc. Announces Changes to its Rights Offering (Business Wire)

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DUGGAN ROBERT W	Director	Dec 11 '24	Buy	17.35	56,054	972,344	42,228,057	Dec 13 07:30 PM
Barrett Burke Thomas	President and CEO	May 20 '24	Buy	8.56	10,000	85,600	10,000	May 22 02:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Pulse Biosciences Inc

Upgrade your FINVIZ experience